Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ziga Rotar

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Rheumatology (Oxford, England)|October 31, 2019
Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpACecilie Heegaard Brahe, Lykke Midtbøll Ørnbjerg, Lennart Jacobsson, et al.
Annals of the Rheumatic Diseases|August 22, 2019
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaborationLykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Johan Askling, et al.
EULAR Rheumatology Open|June 29, 2026
Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort studyAnnik Steimer, Andrea Götschi, Jonas Brändli, et al.
The Journal of Rheumatology|February 1, 2025
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration NetworkMarion Pons, Stylianos Georgiadis, Merete Lund Hetland, et al.
Arthritis Research & Therapy|October 20, 2023
Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaborationLouise Linde, Lykke M Ørnbjerg, Simon H Rasmussen, et al.
RMD Open|September 20, 2020
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaborationBrigitte Michelsen, Ulf Lindström, Catalin Codreanu, et al.
Seminars in Arthritis and Rheumatism|August 19, 2022
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaborationLykke M Ørnbjerg, Louise Linde, Stylianos Georgiadis, et al.
Seminars in Arthritis and Rheumatism|December 4, 2022
Corrigendum to 'Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration' [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081]Lykke M Ørnbjerg, Louise Linde, Stylianos Georgiadis, et al.
Seminars in Arthritis and Rheumatism|February 1, 2024
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practiceSara Nysom Christiansen, Simon Horskjær Rasmussen, Marion Pons, et al.
The Journal of Rheumatology|December 1, 2022
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor TreatmentLykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Rheumatology (Oxford, England)|October 31, 2019
Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpACecilie Heegaard Brahe, Lykke Midtbøll Ørnbjerg, Lennart Jacobsson, et al.
Annals of the Rheumatic Diseases|August 22, 2019
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaborationLykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Johan Askling, et al.
EULAR Rheumatology Open|June 29, 2026
Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort studyAnnik Steimer, Andrea Götschi, Jonas Brändli, et al.
The Journal of Rheumatology|February 1, 2025
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration NetworkMarion Pons, Stylianos Georgiadis, Merete Lund Hetland, et al.
Arthritis Research & Therapy|October 20, 2023
Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaborationLouise Linde, Lykke M Ørnbjerg, Simon H Rasmussen, et al.
RMD Open|September 20, 2020
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaborationBrigitte Michelsen, Ulf Lindström, Catalin Codreanu, et al.
Seminars in Arthritis and Rheumatism|August 19, 2022
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaborationLykke M Ørnbjerg, Louise Linde, Stylianos Georgiadis, et al.
Seminars in Arthritis and Rheumatism|December 4, 2022
Corrigendum to 'Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration' [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081]Lykke M Ørnbjerg, Louise Linde, Stylianos Georgiadis, et al.
Seminars in Arthritis and Rheumatism|February 1, 2024
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practiceSara Nysom Christiansen, Simon Horskjær Rasmussen, Marion Pons, et al.
The Journal of Rheumatology|December 1, 2022
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor TreatmentLykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
Pageof 7